公开(公告)号：US20080181948A1

公开(公告)日：2008-07-31

申请号：US11939640

申请日：2007-11-14

申请人： Gunther Berndl ,  Joerg Rosenberg ,  Bernd Liepold ,  Katja Fastnacht ,  Tina Jung ,  Wolfgang Roth ,  Joerg Breitenbach ,  John Morris ,  Cheri E. Klein ,  Yan Cai ,  Laman Alani ,  Soumojeet Ghosh

发明人： Gunther Berndl ,  Joerg Rosenberg ,  Bernd Liepold ,  Katja Fastnacht ,  Tina Jung ,  Wolfgang Roth ,  Joerg Breitenbach ,  John Morris ,  Cheri E. Klein ,  Yan Cai ,  Laman Alani ,  Soumojeet Ghosh

IPC分类号： A61K9/28 ,  A61K31/427 ,  A61P31/18 ,  A61K9/107

CPC分类号： A61K31/427 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/2095

摘要： The present invention features solid pharmaceutical dosage formulations comprising ritonavir. As a non-limiting example, a dosage form of the present invention comprises a solid dispersion or solid solution of ritonavir in a matrix, where the matrix comprises at least one water-soluble polymer, such as copovidone, and at least one surfactant, such as polyoxyl 40 hydrogenated castor oil or macrogolglycerol hydroxystearate. Preferably, the solid dispersion or solution does not include, or includes only an insignificant amount of, PEG.

摘要翻译： 本发明的特征在于包含利托那韦的固体药物剂型。 作为非限制性实例，本发明的剂型包含利托那韦在基质中的固体分散体或固体溶液，其中基质包含至少一种水溶性聚合物如共聚维酮，和至少一种表面活性剂，例如 作为聚氧乙烯40氢化蓖麻油或聚乙二醇羟基硬脂酸酯。 优选地，固体分散体或溶液不包括或仅包含不显着量的PEG。

公开(公告)号：US08492386B2

公开(公告)日：2013-07-23

申请号：US13603006

申请日：2012-09-04

申请人： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

发明人： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC分类号： A61K31/4965 ,  A61K31/33 ,  A61K31/505 ,  A61K31/47 ,  A61K31/415 ,  A61K31/40 ,  A61K31/675

CPC分类号： A61K38/07 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/473 ,  A61K31/513 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/06 ,  A61K38/12 ,  A61K45/06 ,  G06F17/10 ,  G06F19/12

摘要： The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

公开(公告)号：US20130102558A1

公开(公告)日：2013-04-25

申请号：US13603006

申请日：2012-09-04

申请人： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

发明人： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC分类号： A61K31/7076 ,  A61K31/497 ,  A61K31/513 ,  A61P31/14 ,  A61K31/4709 ,  A61K31/427 ,  A61K31/4178 ,  A61K31/4025 ,  A61K31/7072 ,  A61K31/4725

CPC分类号： A61K38/07 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/427 ,  A61K31/473 ,  A61K31/513 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/06 ,  A61K38/12 ,  A61K45/06 ,  G06F17/10 ,  G06F19/12

摘要： The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

公开(公告)号：US20130102525A1

公开(公告)日：2013-04-25

申请号：US13603022

申请日：2012-09-04

申请人： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

发明人： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC分类号： A61K31/7056 ,  A61P31/14 ,  A61K38/07

CPC分类号： A61K38/07 ,  A61K31/402 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/513 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/12 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

公开(公告)号：US20110166171A1

公开(公告)日：2011-07-07

申请号：US13050077

申请日：2011-03-17

申请人： Yihong Qiu ,  Cheri E. Klein

发明人： Yihong Qiu ,  Cheri E. Klein

IPC分类号： A61K31/485 ,  A61P29/00

CPC分类号： A61K31/485 ,  A61K9/0053 ,  A61K9/20 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2086 ,  A61K9/209 ,  A61K9/2866 ,  A61K9/4808 ,  A61K9/5084 ,  A61K31/167 ,  A61K2300/00

摘要： The present invention relates to monoeximic solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods for providing therapeutic agents to patients in need of treatment.

摘要翻译： 本发明涉及用于给药药剂，特别是氢可酮和对乙酰氨基酚的单一用途固体剂型，用于制备所述剂型的方法，以及向需要治疗的患者提供治疗剂的方法。

公开(公告)号：US08466159B2

公开(公告)日：2013-06-18

申请号：US13603022

申请日：2012-09-04

申请人： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

发明人： Barry M. Bernstein ,  Rajeev M. Menon ,  Amit Khatri ,  Sven Mensing ,  Sandeep Dutta ,  Daniel E. Cohen ,  Thomas J. Podsadecki ,  Scott C. Brun ,  Walid M. Awni ,  Emily O. Dumas ,  Cheri E. Klein

IPC分类号： A61K31/4965 ,  A61K31/33 ,  A61K31/505 ,  A61K31/47 ,  A61K31/415 ,  A61K31/40

CPC分类号： A61K38/07 ,  A61K31/402 ,  A61K31/4025 ,  A61K31/4184 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/513 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7072 ,  A61K38/05 ,  A61K38/12 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.